Abstract
Purpose: :
To assess the response to bevacizumab in different patterns of uveitic macular edema.
Methods: :
34 eyes with uveitic macular edema receiving single (25 eyes) or two doses of bevacizumab intravitreal injections (2.5mg) were prospectively followed for 6 months. Anatomical outcomes were assessed by OCT.
Results: :
Three patterns of macular edema were identified and percentages of eyes showing response (defined as 25% reduction in central foveal thickness) are as follows:diffuse thickening, 29%(4/14) , cystoid edema,56%(9/16), serous detachment without posterior hyaloid traction,50%(2/4). Four eyes each having diffuse thickening and cystoid edema and one eye having serous detachment without posterior hyaloid traction received second doze of intravitreal bevacizumab.
Keywords: macula/fovea • edema • autoimmune disease